RSV Uses Double-Stranded RNA Receptors to Inhibit p53 and Prolong Cell Survival
RSV Uses Double-Stranded RNA Receptors to Inhibit p53 and Prolong Cell Survival
批准号:
7464342
负责人:
DAYNA GROSKREUTZ
金额:
$12.66万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-04-01 至 2013-03-31
关键词:
AffectAgeApoptosisAsthmaAwardBiologicalBronchiolitisCell DeathCell SurvivalCellsCellular biologyChildChronic lung diseaseClinicalClinical TrialsCommitConflict (Psychology)ConsultCritical CareDataDevelopmentDevelopment PlansDoctor of MedicineDouble-Stranded RNAEncephalomyocarditis virusEnsureEnvironmentEpithelial CellsFacultyFutureGenesGenetic TranscriptionHepatocyteIL8 geneImmunocompromised HostImmunologyInfantInfectionInflammationInflammatoryInflammatory ResponseInfluenzaInstitutionInterferonsInterleukin-6LifeLinkLocationLungMediatingMedicineMentorsMolecular and Cellular BiologyNecrosisObstructive Lung DiseasesPaperPathogenesisPathway interactionsPatientsPhysiciansPlayPneumoniaProtein p53PublishingPulmonologyRNARegulationResearchResearch DesignResearch PersonnelResearch ProposalsResourcesRespiratory Syncytial Virus InfectionsRespiratory syncytial virusReview LiteratureRoleScientistSendai virusSignal PathwaySignal TransductionStatistical MethodsTP53 geneTranslationsTumor Suppressor ProteinsUrinationViralVirusVirus DiseasesVirus ReplicationWorkabstractingbasecareercell typeclinically significantinsightmutantnovelpediatric pharmacologyprogramsprotein kinase Rreceptorsensorsuccesstherapeutic targetvirology
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant):
This application is to support the development of Dr. Dayna Groskreutz into an independent investigator and an accomplished physician-scientist. Dr. Gary Hunninghake will assume the responsibility as mentor to ensure the success of the career development plan. Dr. Groskreutz has already taken courses in general research principles and graduate immunology, and career development during this K-08 award will include further coursework in immunology, virology, cell and molecular biology, study design, and statistical methods. The proposed research investigates the effect of RSV infection on double-stranded RNA (dsRNA) receptors in airway epithelial cells and examines how these dsRNA receptors modulate p53 to delay apoptosis and allow for enhanced viral replication. In Aim 1, Dr. Groskreutz will investigate the effect of RSV on the expression and location of dsRNA receptors. In addition, their effect on p53 will be determined by blocking the expression of the dsRNA receptors and evaluating for a change in p53 protein. In Aim 2, Dr. Groskreutz will examine the biological effect of RSV-induced changes in p53 protein. To this end, p53 will be over-expressed and the biological effect of preserved p53 on cell viability, RSV replication, and inflammatory pathways will be determined. Finally, Dr. Groskreutz will evaluate whether specific RSV genes play a role in modulating dsRNA receptors and p53 protein. She will develop and add RSV strains void of the expression of single genes to airway epithelial cells and evaluate their effect on dsRNA receptors and p53. Throughout Dr. Grosrkeutz's career development, she will consult with experts in immunology, virology, cell biology, pharmacology, pediatrics, and pulmonary medicine. This environment will facilitate her development into an independent investigator, and her colleagues will serve as important resources as well as provide critical review of her work. Both her mentor and her institution are committed to her success and career development. As a sign of this commitment, she joined the faculty of the Division of Pulmonary and Critical Care Medicine in July 2006. Dr. Groskreutz's research proposal has great clinical significance. RSV continues to be a perplexing and challenging clinical problem in young children, in patients with chronic lung disease, and in immunosuppressed patients. This research could provide insight into to the cell signaling pathways important to the pathogenesis of RSV infection and identify key therapeutic targets for future clinical trials.
(End of Abstract)
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RSV Uses Double-Stranded RNA Receptors to Inhibit p53 and Prolong Cell Survival
-
批准号:7897867
-
项目类别:
-
资助金额:$12.66万
-
财政年份:2008
-
负责人:DAYNA GROSKREUTZ
-
依托单位:
RSV Uses Double-Stranded RNA Receptors to Inhibit p53 and Prolong Cell Survival
-
批准号:7603028
-
项目类别:
-
资助金额:$12.66万
-
财政年份:2008
-
负责人:DAYNA GROSKREUTZ
-
依托单位:
RSV Uses Double-Stranded RNA Receptors to Inhibit p53 and Prolong Cell Survival
-
批准号:8040028
-
项目类别:
-
资助金额:$12.66万
-
财政年份:2008
-
负责人:DAYNA GROSKREUTZ
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: